Introduction {#Sec1}
============

The management of aortic stenosis has been revolutionized by the introduction of transcatheter aortic valve implantation (TAVI) less than 20 years ago^[@CR1]^. After the first pioneering efforts, several landmark trials using first-generation devices established the superiority of TAVI in comparison to medical therapy encompassing valvuloplasty in patients at prohibitive surgical risk and the non-inferiority of TAVI in comparison to surgical aortic valve replacement in subjects at high or intermediate risk, and, most recently, in low-risk patients^[@CR2],[@CR3]^. Despite these breakthroughs, uncertainty persists on the long-term durability of TAVI and the precise impact of residual aortic regurgitation. Indeed, very long-term (\>10 years) follow-up will be required to accurately gauge these risks^[@CR1]^. Awaiting such strategic data, another area of controversy is the comparison between different TAVI devices.

While all new-generation devices boast important technological refiments including reduced size and skirt to minimize paravalvular leak, there are now at least 7 different TAVI devices available for clinical use^[@CR1]^. Whereas Sapien3 is the only balloon-expandable valve, even among self-expandable devices, which include Acurate, Allegra, Evolut, JenaValve, Lotus, and Portico, differences abound^[@CR4],[@CR5]^. For instance, manufacturers have diversified their products with alternative choices for device length, strut thickness, cell size, radial force, skirt length, and delivery method. To date, few comparative studies have been reported on TAVI devices. In particular, Vlaastra and colleagues showed that Sapien3 may be associated with lower surgical conversion rates, fewer strokes and permanent pacemaker implantations (PPI), but more bleedings than Evolut^[@CR6]^, whereas Pagnesi *et al*. have reported similar short-term results with Acurate and Evolut^[@CR4]^. Other comparative analyses have provided hints at other possible differences as well^[@CR7]--[@CR9]^. Of course, ongoing randomized trials will provide more accurate outcome data, but in the meanwhile, we aimed to inform clinicians and patients on the short-term comparative effectiveness and safety of 5 leading TAVI devices using the clinical data prospectively collected in the Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea (RISPEVA) study^[@CR10]^.

Methods {#Sec2}
=======

Design {#Sec3}
------

The RISPEVA Study has been previously described in detail elsewhere^[@CR10]--[@CR12]^. Briefly, RISPEVA was a national prospective observational study focusing on TAVI conducted in several Italian centers. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the institutional ethics committee of: Policlinico San Donato, San Donato Milanese, Milan; Pineta Grande Hospital, Castel Volturno; Policlinico Santa Maria alle Scotte, Siena; Fondazione C.N.R. G. Monasterio Ospedale del Cuore, Massa; Humanitas University, Rozzano;, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; University of Catania, Catania; Spedali Civili di Brescia, Brescia; University of Pisa, Pisa; University of Turin, Turin; Ospedale Niguarda Ca' Granda, Milan; Clinica Montevergine, Avellino; Centro Cardiologico Monzino, Milan; Anthea Hospital GVM Care&Research, Bari; Sapienza University of Rome-Policlinico Umberto I, Rome; "SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria; Maria Pia Hospital, Turin; San Giovanni di Dio e Ruggi d'Aragona, Salerno; Ospedale di Lecco, Lecco; Azienda Ospedaliera Universitaria di Parma, Parma; Policlinico Universitario Mater Domini, Catanzaro; IRCCS San Martino, Genova; Ospedale Bolognini, Seriate; Ospedale Civile di Legnano, Legnano; Ospedale S. Chiara, Trento; Istituto Clinico San Rocco, Ome; Fondazione Poliambulanza, Brescia; Maria Cecilia Hospital, Cotignola; European Hospital, Rome (all in Italy). Written informed consent was obtained from all subjects. Additional details are also available in the online registration module on clinicaltrials.gov (NCT02713932).

Aims {#Sec4}
----

The main aim of this RISPEVA subanalysis was to compare patients undergoing attempted implantation of Acurate, Evolut, Lotus, Portico, or Sapien3 devices, focusing on short-term (procedural, peri-procedural, and 1-month) outcomes. Labelling was based on attempt to deliver and/or deploy a specific device, and not necessarily on eventually successful implantation.

Patients, procedures, definitions {#Sec5}
---------------------------------

Details on patient and procedures in the RISPEVA Study have also been detailed previously. Briefly, all patients in whom TAVI was attempted at participating centers and willing to provide consent were offered inclusion in the study, without any additional selection criterion. Several baseline, procedural and outcome variables were collected in a dedicated electronic case report form. Procedural outcomes included: contrast volume, fluoroscopy time, procedural time, device success, procedural success, death, valve migration, anulus rupture, surgical conversion, coronary occlusion, myocardial infarction, pericardial tamponade, aortic dissection, major vascular complication, and major bleeding. Follow-up assessments were planned at 1 month after TAVI and subsequently. In particular, details on the following clinically relevant outcomes were systematically collected: death, cardiac death, surgical aortic valve replacement, valve thrombosis, valve degeneration, endocarditis, coronary occlusion, myocardial infarction, pericardial effusion, stroke, transient ischemic attack, major vascular complication, amputation, major bleeeding, renal failure, and PPI. Echocardiographic assessment was routinely performed at admission, at discharge, and at 1-month, focusing on the following endpoints: veft ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LEVF), peak aortic gradient, mean aortic gradient, aortic valve area, aortic regurgitation, mitral regurgitation, and systolic pulmonary artery pressure (SPAP). Major adverse events, a composite of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure, were also computed. All definitions originated by the current Valve Academic Research Consortium recommendations^[@CR13]^.

Statistical analysis {#Sec6}
--------------------

Continous variables are reported as mean ± standard deviation, and categorical variables as count (%). Unadjusted analysis was based on analysis of variance for continuous variables and chi^2^ test for categorical variables. Adjusted analysis was based on propensity score adjusted generalized linear models with default link for continuous variables and binomial likelihood for binary variables, using missing data imputation when appropriate. Pairwise propensity scores were generated using several baseline and procedural variables (Online supplement). Statistical significance for hypothesis testing was be set at the two-tailed 0.05 level, without multiplicity adjustment. Computations were performed with Stata 13 (StataCorp, College Station, TX).

Results {#Sec7}
=======

Baseline features {#Sec8}
-----------------

A total of 1976 patients were included, who underwent TAVI between 2012 and 2018, mostly in 7 high volume centers (Table [S1](#MOESM1){ref-type="media"}): 234 (11.8%) treated with Acurate, 703 (35.6%) with Evolut, 151 (7.6%) with Lotus, 347 (17.6%) with Portico, and 541 (27.4%) with Sapien3. Baseline features are provided in Table [1](#Tab1){ref-type="table"}, with additional details in Table [S1](#MOESM1){ref-type="media"}. Several differences in baseline features, with complex patterns in favor or against a given device, were found (Fig. [S1](#MOESM1){ref-type="media"}). Specifically, there were significant differences in age, gender (with more females receiving Acurate and Portico), height, BMI, diagnosis, risk (with more inoperable patients receiving Evolut), Logistic EuroSCORE (with lower values in those receiving Acurate), EuroSCORE II, and STS score (all p \< 0.05). Similarly, significant differences were found in NYHA class, prior valvuloplasty, peak aortic gradient, aortic valve area, aortic regurgitation, porcelain aorta, family history of CAD, hypertension, current smoking, prior CAD, angiographic CAD, prior acute pulmonary edema, prior myocardial infarction, prior percutaneous coronary intervention, syncope, carotid artery disease, peripheral artery disease, systolic blood pressure, diastolic blood pressure, hematocrit, oxygen dependency, prior cancer, LVEDV, LVESV, bicuspid aortic valve, and ilio-femoral tortuosity (all p \< 0.05).Table 1Baseline features at unadjusted analysis.FeatureAcurateEvolutLotusPorticoSapien3PPatients234703151347541---Age (years)83.5 ± 6.082.1 ± 6.782.0 ± 6.582.5 ± 6.583.1 ± 6.50.015Female gender156 (66.7%)391 (55.6%)83 (55.0%)223 (64.3%)288 (53.2%)\<0.001Body mass index (kg/m^2^)26.1 ± 4.526.1 ± 4.425.4 ± 3.926.8 ± 4.626.1 ± 4.60.045Diagnosis\<0.001    Aortic stenosis217 (92.7%)593 (85.4%)129 (85.4%)291 (83.9%)472 (87.3%)    Mixed aortic valve disease9 (3.9%)76 (10.8%)18 (11.9%)15 (4.3%)53 (9.8%)Aortic regurgitation5 (2.1%)17 (2.4%)1 (0.7%)1 (0.3%)2 (0.4%)    Degenerated bioprosthesis3 (1.3%)17 (2.4%)3 (2.0%)40 (11.5%)14 (2.6%)Risk\<0.001    Inoperable5 (2.1%)45 (6.4%)5 (3.3%)6 (1.7%)50 (9.2%)    High195 (83.3%)618 (87.9%)141 (93.4%)278 (80.1%)433 (80.0%)    Intermediate34 (14.5%)40 (5.7%)5 (3.3%)63 (18.2%)58 (10.7%)Logistic EuroSCORE12.9 ± 11.016.7 ± 11.616.3 ± 14.516.2 ± 11.616.7 ± 12.1\<0.001EuroSCORE II4.1 ± 4.25.0 ± 4.95.0 ± 6.14.2 ± 3.95.5 ± 4.8\<0.001STS score5.0 ± 3.85.6 ± 4.15.1 ± 4.26.3 ± 4.25.4 ± 4.20.054New York Heart Association class\<0.001    I1 (0.4%)6 (0.9%)5 (3.3%)9 (2.6%)13 (2.4%)    II70 (30.0%)210 (31.8%)35 (23.2%)80 (23.1%)187 (34.6%)    III159 (68.2%)407 (61.6%)104 (68.9%)251 (72.3%)323 (59.7%)    IV3 (1.3%)38 (5.8%)7 (4.6%)7 (2.0%)18 (3.3%)Prior cardiac surgery21 (9.0%)38 (5.4%)13 (8.6%)22 (6.3%)40 (7.4%)0.276Prior aortic valvuloplasty12 (5.1%)33 (4.7%)13 (8.6%)14 (4.0%)52 (9.6%)0.001Pacemaker dependency25 (10.7%)50 (7.1%)13 (8.6%)31 (8.9%)39 (7.2%)0.407Prior stroke or transient ischemic attack21 (9.0%)38 (5.4%)13 (8.6%)22 (6.3%)40 (7.4%)0.276Estimated glomerular filtration rate (mL/min)65.1 ± 23.062.2 ± 23.866.5 ± 47.761.1 ± 24.862.6 ± 23.60.217Left ventricular ejection fraction (%)53 ± 1152 ± 1053 ± 1254 ± 1053 ± 100.424Peak aortic gradient (mm Hg)75.4 ± 21.376.4 ± 22.977.7 ± 23.471.4 ± 23.677.7 ± 20.90.014Mean aortic gradient (mm Hg)47.8 ± 13.847.3 ± 14.948.0 ± 14.848.0 ± 16.848.2 ± 13.80.896Aortic valve area (cm2)0.67 ± 0.230.67 ± 0.260.66 ± 0.240.69 ± 0.240.63 ± 0.180.040Aortic regurgitation\<0.001None89 (38.0%)204 (29.0%)45 (29.8%)140 (40.4%)124 (22.9%)    1+96 (41.0%)320 (45.5%)71 (47.0%)123 (35.5%)302 (55.8%)    2+36 (15.4%)136 (19.4%)29 (19.2%)68 (19.6%)103 (19.0%)    3+13 (5.6%)43 (6.1%)6 (4.0%)16 (4.6%)12 (2.2%)Porcelain aorta8 (3.4%)58 (8.3%)9 (6.0%)4 (1.2%)49 (9.1%)\<0.001Angiographically significant coronary artery disease62 (26.5%)198 (28.2%)34 (22.5%)44 (12.7%)140 (25.9%)\<0.001Iliofemoral tortuosity\<0.001    Mild73 (64.0%)121 (33.8%)41 (49.4%)100 (40.2%)135 (47.2%)    Moderate39 (34.2%)193 (53.9%)40 (48.2%)145 (58.2%)127 (44.4%)    Severe2 (1.8%)44 (12.3%)2 (2.4%)4 (1.6%)24 (8.4%)

Procedural features {#Sec9}
-------------------

Procedural characteristics were also different in many domains (Table [2](#Tab2){ref-type="table"}), including local anesthesia, transesophageal guidance, femoral access, sheathless procedure, sheath size, embolic protection device, right ventricular pacing, predilation, predilation balloon diameter, predilation balloon type, prostheses number, device size, pacing during implant, pacing rate, postdilation, postdilation balloon diameter, and postdilation balloon diameter (all p \< 0.05). In particular, transesophageal guidance was less common with Evolut and Sapien3, smaller balloons were used with Lotus, pacing was more common with Evolut and Sapien3, and postdilation less prevalent with Lotus and Sapien3 (all p \< 0.05). Despite such differences, procedural and device success were both very high, ranging between 98% and 99%, and non-significantly different across devices. Similarly, unadjusted procedural rates of death, anulus rupture, surgical conversion, coronary occlusion, myocardial infarction, pericardial tamponade, aortic dissection, or major vascular complications were all similar (all p \> 0.05), whereas valve migration was more common with Acurate, and major bleeding with Sapien3 (both p \< 0.05).Table 2Procedural features at unadjusted analysis.FeatureAcurateEvolutLotusPorticoSapien3PPatients234703151347541---Local anesthesia202 (86.3%)594 (84.5%)134 (88.7%)313 (90.2%)420 (77.6%)\<0.001Transephageal guidance76 (32.5%)10 (1.4%)47 (31.1%)128 (36.9%)51 (9.4%)\<0.001Femoral access216 (92.3%)612 (87.1%)141 (93.4%)303 (87.3%)510 (94.3%)\<0.001Percutaneous approach208 (88.9%)616 (87.6%)130 (86.1%)305 (87.9%)464 (85.8%)0.732Sheathless procedure5 (2.1%)160 (22.8%)4 (2.7%)6 (1.7%)26 (4.8%)\<0.001Sheath size (French)18.4 ± 2.115.1 ± 1.718.4 ± 1.818.4 ± 0.714.5 ± 1.7\<0.001Embolic protection device\<0.001   None232 (99.2%)702 (99.9%)150 (99.3%)345 (99.4%)519 (95.9%)   Claret1 (0.4%)1 (0.1%)1 (0.7%)2 (0.6%)20 (3.7%)   Shimon1 (0.4%)0002 (0.4%)Right ventricular pacing118 (50.4%)422 (60.0%)60 (39.7%)192 (55.3%)452 (83.6%)\<0.001Predilation\<0.001   None82 (35.0%)272 (38.7%)93 (61.6%)117 (33.7%)92 (17.0%)   One balloon149 (63.7%)417 (59.3%)58 (38.4%)225 (64.8%)449 (83.0%)   Two balloons3 (1.3%)14 (2.0%)05 (1.4%)0Balloon diameter (mm)21.8 ± 2.920.4 ± 2.020.3 ± 1.920.7 ± 1.621.6 ± 2.0\<0.001Balloon type\<0.001   Cristal52 (34.2%)19 (4.4%)025 (10.9%)7 (1.6%)   Nucleus3 (2.0%)37 (8.5%)7 (12.1%)04 (0.9%)   Z.Med24 (15.8%)72 (16.6%)23 (39.7%)1 (0.4%)4 (0.9%)   Other73 (48.0%)307 (70.6%)28 (48.3%)204 (88.7%)434 (96.7%)Prosthesis0.029   One230 (98.3%)681 (96.9%)150 (99.3%)340 (98.0%)537 (99.3%)   Two4 (1.7%)22 (3.1%)1 (0.7%)7 (2.0%)4 (0.7%)Heterogenous device1 (0.4%)00000.114Device size (French)25.0 ± 2.128.1 ± 3.124.9 ± 2.026.4 ± 2.225.0 ± 2.4\<0.001Pacing during implant71 (30.3%)152 (21.6%)16 (10.6%)18 (5.2%)501 (92.6%)\<0.001Pacing rate (bpm)181 ± 25158 ± 36145 ± 59163 ± 24182 ± 12\<0.001Postdilation111 (47.4%)202 (28.7%)2 (1.3%)165 (47.6%)27 (5.0%)\<0.001Balloon diameter (mm)23.2 ± 1.924.1 ± 2.620 ± 023.9 ± 2.022.4 ± 2.1\<0.001Balloon length (mm)42.1 ± 4.740.8 ± 2.440.0 ± 041.1 ± 2.940.9 ± 7.40.415Fluoroscopy time (seconds)22.7 ± 13.526.3 ± 16.330.0 ± 11.026.4 ± 14.121.5 ± 14.8\<0.001Procedural time (minutes)120.5 ± 50.8113.0 ± 51.5104.5 ± 39.687.4 ± 43.1113.1 ± 46.6\<0.001Device success232 (99.2%)693 (98.6%)148 (98.0%)343 (98.9%)533 (98.5%)0.899Procedural success232 (99.2%)693 (98.6%)148 (99.4%)345 (99.4%)533 (98.5%)0.627Complications   Death1 (0.4%)2 (0.3%)3 (2.0%)1 (0.3%)6 (1.1%)0.085   Valve migration5 (2.1%)7 (1.0%)001 (0.2%)0.007   Anulus rupture00002 (0.4%)0.257   Surgical conversion01 (0.1%)1 (0.7%)2 (0.6%)2 (0.4%)0.576   Coronary occlusion01 (0.1%)002 (0.4%)0.590   Myocardial infarction01 (0.1%)001 (0.2%)0.873   Pericardial tamponade1 (0.4%)2 (0.3%)3 (2.0%)2 (0.6%)8 (1.5%)0.069   Aortic dissection03 (0.4%)03 (0.9%)2 (0.4%)0.492   Major vascular complication7 (3.0%)25 (3.6%)5 (3.3%)11 (3.2%)21 (3.9%)0.969   Major bleeding8 (3.4%)39 (5.6%)5 (3.3%)8 (2.3%)43 (8.0%)0.002

Unadjusted analysis for one-month outcomes {#Sec10}
------------------------------------------

Most one-month outcomes were similar across devices (Table [3](#Tab3){ref-type="table"}), including death, cardiac death, surgical aortic valve replacement, valve thrombosis, valve degeneration, endocarditis, coronary occlusion, myocardial infarction, stroke, transient ischemic attack, amputation, and major bleeding (all p \> 0.05). However, significant differences were found for major adverse events (p \< 0.001, with lowest rates for Portico), pericardial effusion (p \< 0.001, with lowest rates for Portico), major vascular complication (p \< 0.001, with lowest rates for Portico), and PPI (p \< 0.001, with lowest rates for Acurate). Echocardiographic follow-up showed differences in LVEDD, peak aortic gradient, mean aortic gradient, aortic valve area, aortic regurgitation, and mitral regurgitation (all p \< 0.05).Table 3One-month outcomes at unadjusted analysis.FeatureAcurateEvolutLotusPorticoSapien3PPatients234703151347541---Clinical outcomes   Major adverse event\*60 (25.6%)135 (19.2%)24 (15.9%)40 (11.5%)131 (24.2%)\<0.001   Death4 (1.7%)11 (1.6%)4 (2.7%)8 (2.3%)8 (1.5%)0.794   Cardiac death1 (0.4%)4 (0.6%)3 (2.0%)2 (0.6%)6 (1.1%)0.357   Surgical aortic valve replacement01 (0.1%)1 (0.7%)3 (0.9%)2 (0.4%)0.320   Valve thrombosis02 (0.3%)001 (0.2%)0.742   Valve degeneration000001   Endocarditis000001   Coronary occlusion01 (0.1%)002 (0.4%)0.590   Myocardial infarction02 (0.3%)002 (0.4%)0.650   Pericardial effusion12 (5.1%)27 (3.8%)6 (4.0%)8 (2.3%)46 (8.5%)\<0.001   Stroke1 (0.4%)12 (1.7%)4 (2.7%)2 (0.6%)7 (1.3%)0.216   Transient ischemic attack02 (0.3%)01 (0.3%)00.618   Stroke or transient ischemic attack1 (0.4%)13 (1.9%)4 (2.7%)3 (0.9%)7 (1.3%)0.283   Major vascular complication33 (14.1%)61 (8.7%)8 (5.3%)17 (4.9%)68 (12.6%)\<0.001   Amputation000001   Major bleeeding10 (4.3%)20 (2.8%)7 (4.6%)9 (2.6%)27 (5.0%)0.218   Renal failure26 (11.1%)63 (9.0%)9 (6.0%)16 (4.6%)47 (8.7%)0.035   Permanent pacemaker13 (5.6%)122 (17.4%)35 (23.2%)42 (12.1%)72 (13.3%)\<0.001Echocardiographic outcomes   Left ventricular end-diastolic diameter (mm)45.6 ± 9.349.2 ± 10.549.6 ± 8.146.7 ± 6.949.1 ± 8.50.002   Left ventricular end-systolic diameter (mm)32.1 ± 8.232.3 ± 10.533.2 ± 9.531.6 ± 8.032.1 ± 11.50.971   Left ventricular ejection fraction (%)55.2 ± 9.553.3 ± 9.652.9 ± 10.454.2 ± 9.153.2 ± 9.20.051   Peak aortic gradient (mm Hg)16.0 ± 9.515.3 ± 7.919.6 ± 14.018.2 ± 13.221.6 ± 11.5\<0.001   Mean aortic gradient (mm Hg)9.2 ± 0.4.48.2 ± 4.612.1 ± 5.49.4 ± 6.111.6 ± 5.1\<0.001   Aortic valve area (mm2)1.17 ± 0.471.43 ± 0.491.28 ± 0.371.04 ± 0.471.37 ± 0.47\<0.001Aortic regurgitation\<0.001   None44 (20.9%)207 (35.3%)91 (67.4%)133 (44.5%)240 (50.0%)   1+135 (64.0%)309 (52.7%)40 (29.6%)139 (46.5%)224 (46.7%)   2+32 (15.2%)66 (11.3%)4 (3.0%)26 (8.7%)16 (3.3%)   3+04 (0.7%)01 (0.3%)0   4+00000Mitral regurgitation\<0.001   None12 (5.2%)42 (7.0%)6 (4.2%)20 (6.0%)21 (4.0%)   1+131 (57.2%)367 (61.0%)87 (60.4%)199 (59.8%)263 (50.3%)   2+64 (28.0%)37 (6.2%)42 (29.2%)86 (25.8%)193 (36.9%)   3+15 (6.6%)140 (23.3%)8 (5.6%)20 (6.0%)36 (6.9%)   4+7 (3.1%)16 (2.7%)1 (0.7%)8 (2.4%)10 (1.9%)   Systolic pulmonary artery pressure (mm Hg)36.7 ± 11.838.1 ± 15.038.2 ± 11.937.8 ± 11.035.5 ± 9.50.052^\*^Composite of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure.

Adjusted analysis {#Sec11}
-----------------

Propensity score-adjusted analysis for selected endpoints is provided in Table [S3](#MOESM1){ref-type="media"}. Specifically, major adverse events were fewest with Evolut (p = 0.040 vs Sapien3) and Portico (p = 0.016 vs Acurate) (Fig. [1](#Fig1){ref-type="fig"}), major vascular complications were less common with Evolut (p = 0.036 vs Lotus, p = 0.002 vs Sapien3), Lotus (p = 0.024 vs Sapien3), and Portico (p = 0.040 vs Acurate, p = 0.010 vs Evolut) (Fig. [2](#Fig2){ref-type="fig"}), renal failure was less frequent with Sapien3 (p = 0.001 vs Acurate) (Fig. [3](#Fig3){ref-type="fig"}), and PPI was less common with Acurate (p = 0.002 vs Evolut, p \< 0.001 vs Lotus, p = 0.043 vs Sapien3) (Fig. [4](#Fig4){ref-type="fig"}).Figure 1Forest plot of propensity score-adjusted analysis for major adverse events (composite of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure).Figure 2Forest plot of propensity score-adjusted analysis for major vascular complication.Figure 3Forest plot of propensity score-adjusted analysis for renal failure.Figure 4Forest plot of propensity score-adjusted analysis for permanent pacemaker implantation.

Adjusted analysis for echocardiographic features suggested lower mean aortic gradients with Acurate (p = 0.002 vs Lotus, p = 0.023 vs Sapien3), Evolut (p \< 0.001 vs Lotus, p \< 0.001 vs Sapien3), and Portico (p = 0.033 vs Lotus, p = 0.043 vs Sapien3), less aortic regurgitation ≥ 2 + /4+ with Sapien3 (p = 0.045 vs Acurate, p = 0.030 vs Evolut, p = 0.017 vs Portico) and Lotus (p = 0.025 vs Acurate), and less mitral regurgitation with Evolut (p = 0.017 vs Portico, p \< 0.001 vs Sapien3) (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Forest plot of propensity score-adjusted analysis for aortic regurgitation implantation ≥2+.

Additional analysis {#Sec12}
-------------------

For exploratory purposes, we also appraised the impact of overall TAVI experience per center, as well as device-specific experience (Tables [S4](#MOESM1){ref-type="media"}; [S5](#MOESM1){ref-type="media"}). At unadjusted analysis using tertiles, instituions at high overall volume showed lower rates of major adverse events, death, and myocardial infarction than other centers (all p \< 0.05), whereas PPI appeared less common in low volume institutions (p = 0.009). Device-specific experience did not seemed associated with significant differences in outcomes, with the notable exception of the risk of death with Lotus, which appeared higher in institutions less experienced with this device (p = 0.010).

Additional sensitivity inferential analyses were conducted forcing in the propensity score-adjusted model overall and device-specific experience (Table [S6](#MOESM1){ref-type="media"}). These analyses, albeit limited by multiplicity issues, suggested that in more experienced settings Portico outperformed Acurate (p = 0.012) and Evolut proved better than Sapien3 (p = 0.045). Focusing on device-specific institutional experience, Portico proved better than Evolut in centers experienced with the latter device (p = 0.015), whereas in the same setting Evolut proved nonetheless better than Sapien3 (p = 0.025).

Discussion {#Sec13}
==========

Main findings {#Sec14}
-------------

This analysis of the RISPEVA study focusing on short-term outcomes following TAVI with 5 leading new-generation devices, despite its mainly descriptive and hypothesis-generating scope, has the following implications: (a) centers and operators performing TAVI used different devices based on preference, training, experience, and patient features; (b) despite substantial differences in baseline and procedural features, ranging from age and gender to subtleties such as pacing or transesophageal guidance, rates of device and procedural success, as well as those of several procedural outcomes including death, appeared largely similar with Acurate, Evolut, Lotus, Portico and Sapien3; (c) accordingly, one-month outcomes appeared quite similar across devices, with encouraging results in terms of death (\<3% for all devices), as well as myocardial infarction, stroke and major bleeding; (d) differences were however apparent across devices for major vascular complications, renal failure and PPI; (e) propensity score-adjusted analysis confirmed such trends, highlighting that these devices may not be considered completely equivalent, and individualized decision making and device choice probably remain important to maximize the risk-benefit and cost-benefit profile of TAVI.

The present findings appear important and timely, and supplement recent ones by other investigators who aimed at comparing different TAVI devices^[@CR1]^. Overall, all recent reports reaffirm the safety of TAVI, confirming its established role in patients with aortic stenosis at intermediate to prohibitive surgical risk, and sustaining recent trials testing the role of TAVI in low risk patients^[@CR2],[@CR3]^. Indeed, major adverse events were quite uncommon, despite this being a pragmatic registry without any specific selection or exclusion criteria. Yet, uncertainty persists on the long-term durability of TAVI, especially in light of recent reports on valve deterioration and leaflet thrombosis (albeit typically silent)^[@CR4]--[@CR6]^. Indeed, structural valve degeneration occurred in 8.7% of patients receiving first-generation TAVI devices after a median follow-up of 5.8 years in the UK TAVI Registry, similar to the 4.8% estimate provided after 6 years of follow-up in the Nordic Aortic Valve Intervention (NOTION) trial^[@CR14],[@CR15]^. Accordingly, much emphasis must be given to the long-term comparative safety and efficacy of TAVI, especially when considering lower risk patients as potential candidates. Despite the ever accruing evidence base, operators are faced with novel devices or refinements of existing ones, with uncertainty on their incremental differences.

Context {#Sec15}
-------

Balloon-expandable devices have been originally considered superior to self-expandable devices in terms of PPI and aortic regurgitation rates, but were associated with higher rates of strokes and vascular complications, at least in some series or comparisons^[@CR16],[@CR17]^. More recent data support the existence of meaningful differences between Evolut and Sapien, between Evolut and Portico, and possibly between Lotus and Sapien3^[@CR9],[@CR12]^. Furthermore, the temporary recall of Lotus depended on engineering issues likely of clinical impact, despite this device usefulness in minimizing aortic regurgitation, albeit at the potential expense of an increase in PPI rates. Other notices of caution or recalls have been recently issued for Sapien3. Thus, attentive focus on each device strenths and weaknesses is paramount. Indeed, in light of prior and recent comparative studies on new-generation TAVI devices as well as our own present ones, we may first infer that experienced operators who have confidence with a given device can obtain satisfactory results with any chosen product, but probably each institution should consider becoming familiar with at least two devices with different features, in order to maximize the benefit of individualized device choice, without compromising skills. Indeed, in keeping with our head-to-head comparisons, it appears that Portico and Evolut are associated with lower rates of major adverse events (p = 0.016 in favor of Portico when compared to Acurate; p = 0.040 in favor of Evolut when compared to Sapien3), Portico with fewer vascular complications (p \< 0.05 in its favor when compared to Acurate and Evolut), Sapien3 with fewer renal failures (p = 0.001 in its favor when compared to Acurate), and Acurate with lower PPI rates (p \< 0.05 in its favor when compared to Evolut, Lotus, and Sapien3). Echocardiographic analyses showed lower gradients with Acurate, Evolut and Portico, with aortic regurgitation and paravalvular leak appearing less common with Lotus and Sapien3. Notably, mean echocardiographic gradients appeared superior in self-expandable valves than in mechanically or balloon-expandable valves irrespective of valve-anulus-height, with potentially detrimental impact on long-term durability.

Focusing on institutional experience with TAVI in general and with specific devices, we found intriguing hypothesis-generating data, suggesting that clinical outcomes are better in higher volume centers, except for PPI, whose rates may indeed depend on local management protocols. Focusing on specific devices, only Lotus seemed significantly dependant on experience. Furthermore, we found that overall and device-specific experience did not dilute significant differences between devices, with persistent evidence that Portico outperformed Acurate and Evolut, with the latter still having an edge in comparison to Sapien3. Yet, these findings, while intriguing, need confirmation in long-term follow-up from RISPEVA and, most importantly, from ongoing comparative randomized trials^[@CR1]^.

Limitations {#Sec16}
-----------

On top of being limited by the non-randomized design, short-term follow-up, and reliance on propensity score adjustment, this study is limited by incomplete data collection for several ancillary baseline features such as frailty, absence of an imaging core lab, and lack of systematic endpoint adjudication. In addition, very few cases of TAVI with other devices such as JenaValve or Allegra were collected, and these devices were thus excluded from analysis. Notably, residual confounding cannot be excluded and might drive some important differences, even after propensity score adjustment, such as for vascular complications. In addition, while we attempted at exploring the impact of institutional experience with TAVI in general and with specific devices as well, operator volume and experience was not collected in the case report form, and thus could not be analyzed.

Conclusion {#Sec17}
==========

New-generation TAVI devices have different profiles of early comparative safety and efficacy. These findings should be taken into account for individualized decision making and patient management.
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